Drugs / APS
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02262364 | Nov 2014 → Oct 2016 | osteoarthritis, knee | Zimmer Biomet | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | APS | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02262364 ↗ |
| Known as | NStride Autologous Protein Solution | “Safety of NStride Autologous Protein Solution in the Treatment of Knee Osteoarthritis (PROGRESS I)” NCT02262364 ↗ |
| Modality | Protein / enzyme biologic | “Autologous Protein Solution” NCT02262364 ↗ |
| Route | Other | “Subjects will receive an intra-articular injection of APS.” NCT02262364 ↗ |